Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Department of Colorectal Surgery, Manchester University NHS Foundation Trust, Manchester, UK.
BJS Open. 2023 Jan 6;7(1). doi: 10.1093/bjsopen/zrac168.
Overall survival rates for locally recurrent rectal cancer (LRRC) continue to improve but the evidence concerning health-related quality of life (HrQoL) remains limited. The aim of this study was to describe the short-term HrQoL differences between patients undergoing surgical and palliative treatments for LRRC.
An international, cross-sectional, observational study was undertaken at five centres across the UK and Australia. HrQoL in LRRC patients was assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29 and functional assessment of cancer therapy - colorectal (FACT-C) questionnaires and subgroups (curative versus palliative) were compared. Secondary analyses included the comparison of HrQoL according to the margin status, location of disease and type of treatment. Scores were interpreted using minimal clinically important differences (MCID) and Cohen effect size (ES).
Out of 350 eligible patients, a total of 95 patients participated, 74.0 (78.0 per cent) treated with curative intent and 21.0 (22.0 per cent) with palliative intent. Median time between LRRC diagnosis and HrQoL assessments was 4 months. Higher overall FACT-C scores denoting better HrQoL were observed in patients undergoing curative treatment, demonstrating a MCID with a mean difference of 18.5 (P < 0.001) and an ES of 0.6. Patients undergoing surgery had higher scores denoting a higher burden of symptoms for the EORTC CR29 domains of urinary frequency (P < 0.001, ES 0.3) and frequency of defaecation (P < 0.001, ES 0.4). Higher overall FACT-C scores were observed in patients who underwent an R0 resection versus an R1 resection (P = 0.051, ES 0.6). EORTC CR29 scores identified worse body image in patients with posterior/central disease (P = 0.021). Patients undergoing palliative chemoradiation reported worse HrQoL scores with a higher symptom burden on the frequency of defaecation scale compared with palliative chemotherapy (P = 0.041).
Several differences in short-term HrQoL outcomes between patients undergoing curative and palliative treatment for LRRC were documented. Patients undergoing curative surgery reported better overall HrQoL and a higher burden of pelvic symptoms.
局部复发性直肠癌(LRRC)的总生存率持续提高,但有关健康相关生活质量(HrQoL)的证据仍然有限。本研究的目的是描述接受 LRRC 手术和姑息治疗的患者之间短期 HrQoL 的差异。
在英国和澳大利亚的五个中心进行了一项国际性、横断面、观察性研究。使用欧洲癌症研究与治疗组织(EORTC)QLQ-CR29 和癌症治疗功能评估-结直肠癌(FACT-C)问卷评估 LRRC 患者的 HrQoL,并对亚组(治愈性与姑息性)进行比较。次要分析包括根据边缘状态、疾病部位和治疗类型比较 HrQoL。使用最小临床重要差异(MCID)和 Cohen 效应大小(ES)解释分数。
在 350 名符合条件的患者中,共有 95 名患者参与了研究,其中 74.0%(78.0%)接受了治愈性治疗,21.0%(22.0%)接受了姑息性治疗。LRRC 诊断和 HrQoL 评估之间的中位时间为 4 个月。接受治愈性治疗的患者的总体 FACT-C 评分较高,表明 HrQoL 较好,具有 MCID,平均差异为 18.5(P < 0.001),ES 为 0.6。接受手术的患者在 EORTC CR29 领域的尿频率(P < 0.001,ES 0.3)和排便频率(P < 0.001,ES 0.4)方面的症状负担更高,得分更高。与 R1 切除相比,接受 R0 切除的患者的总体 FACT-C 评分更高(P = 0.051,ES 0.6)。EORTC CR29 评分表明,后/中央疾病患者的身体形象更差(P = 0.021)。与姑息性化疗相比,接受姑息性放化疗的患者在排便频率量表上的症状负担更高,报告的 HrQoL 评分更差(P = 0.041)。
记录了接受 LRRC 手术和姑息治疗的患者之间短期 HrQoL 结果的几个差异。接受根治性手术的患者报告总体 HrQoL 更好,骨盆症状负担更高。